🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care

RecruitingPhase 3Ages 55 Years - anyAllRegion Stockholm
NCT07187570 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to learn if drug dapagliflozin, a sodium-glucose transport-2 inhibitor, works to treat atrial fibrillation in adults. The main question it aims to answer is: • Does the drug dapagliflozin reduce the recurrence rate of atrial fibrillation? Researchers will compare drug dapagliflozin to standard therapy to see if drug dapagliflozin reduce the recurrence of atrial fibrillation. Persons with atrial fibrillation who are planned for an electric cardioversion will: * Take the drug dapagliflozin, or no drug, once a day for a maximum of 56 days * Undergo a planned electric cardioversion of the atrial fibrillation * Record the rhythm with a hand-held device that transmits the signal to researchers during the study period, but no longer than for 56 days

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with AF on ECG who are planned for electrical cardioversion within 7-26 days from inclusion-date. * Age ≥ 55 years. * Provided written informed consent. Exclusion Criteria: * Current treatment with an SGLT2 inhibitor. * Prior/current diagnosis of heart failure. * Type 1 diabetes mellitus. * Estimated glomerular filtration rate (eGFR) \< 25 mL/min/1.73m2. * Pulmonary vein isolation within preceding 3 months or planned pulmonary vein isolation during the study period (56 days). * Contraindications to SGLT2 inhibitors. * Any condition or circumstance in which the patient should not participate in the study according to the study investigator.
💊

What it tests

  • Dapagliflozin 10 mg once daily
📍

Where

7 sites
Linköping university hosptial
Linköping, Sweden
Örebro University hospital
Örebro, Sweden
Södersjukhuset
Stockholm, Sweden
Karolinska University Hospital
Stockholm, Sweden
Danderyds Hospital
Stockholm, Sweden
Norrlands universitetssjukhus
Umeå, Sweden
Akademiska sjukhuset
Uppsala, Sweden
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy